|
Market Closed -
Nasdaq
21:00:00 25/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 9.240 USD | +6.33% |
|
+1.65% | -12.00% |
| 08-25 | Immatics Announces $150 Million Underwritten Offering | MT |
| 08-18 | Immatics' Q2 Net Loss Narrows as Revenue Rises | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| IMMATICS N.V. | Bio Therapeutic Drugs | +6.33% | +1.65% | -12.00% | +76.67% | -23.26% | 1.26B |
- Stock Market
- Stocks
- IMTX Stock
- Charts Immatics N.V.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
















